Yomeishu Seizo plans to apply its 101,000 shares of Hisamitsu Pharmaceutical Co., Inc. in Taiyo Kosan’s tender offer at approximately 6,082 yen\/share, totaling about 614 million yen. An extraordinary income of approximately 413 million yen is expected to be recorded in the fiscal year ending March 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2540","jir_company_name":"Yomeishu Seizo Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/2540-20260210-01.pdf","jir_short_summary":"Yomeishu Seizo plans to apply its 101,000 shares of Hisamitsu Pharmaceutical Co., Inc. in Taiyo Kosan's tender offer at approximately 6,082 yen\/share, totaling about 614 million yen. An extraordinary income of approximately 413 million yen is expected to be recorded in the fiscal year ending March 2026.","jir_summary":"### Reason for Applying to the Tender Offer\nYomeishu Seizo Co., Ltd. has resolved to apply the 101,000 shares of Hisamitsu Pharmaceutical Co., Inc. it owns to the tender offer conducted by Taiyo Kosan Co., Ltd. Based on the board of directors\u2019 decision and the supportive opinion of Hisamitsu Pharmaceutical\u2019s board, the purchase price and other conditions were judged reasonable, and it was determined that this contributes to enhancing corporate value.\n\n### Number of Shares to be Tendered, Purchase Price, and Future Outlook\nThe number of shares to be tendered is 101,000 shares, resulting in zero shares owned post-application. The planned purchase price is 6,082 yen per share, with a planned total sale amount of 614 million yen. The tender offer period is scheduled from January 7, 2026, to February 19, 2026, with settlement starting on February 27, 2026. From this sale, an extraordinary gain of 413 million yen as investment securities sale profit is expected to be recorded in the fiscal year ending March 2026, with no revision to earnings guidance.","jir_financial_highlights":"Number of shares to be tendered: 101,000 shares (Unknown)\nPlanned purchase price (per share): 6,082 yen (Unknown)\nPlanned total sale amount: 614 million yen (Unknown)\nExpected recording of extraordinary income: 413 million yen (Unknown)","jir_category":"","jir_hashtags":"#YomeishuSeizo, #TenderOffer, #ExtraordinaryIncome, #JapaneseStocks","jir_key_figures":"Number of shares to be tendered: 101,000 shares\nPlanned purchase price: 6,082 yen\/share\nPlanned total sale amount: 614 million yen\nExpected recording of extraordinary income: 413 million yen","jir_meta_title":"Yomeishu Seizo to Sell 101,000 Hisamitsu Pharmaceutical Shares through Tender Offer, Expected Extraordinary Income of 413 Million Yen","jir_meta_description":"Yomeishu Seizo Co., Ltd. will apply its 101,000 shares of Hisamitsu Pharmaceutical Co., Inc. to Taiyo Kosan\u2019s tender offer and sell them at approximately 6,082 yen per share. An extraordinary income of 413 million yen is expected to be recorded in the fiscal year ending March 2026.","jir_og_title":"Yomeishu Seizo Announces Application to Tender Offer of Hisamitsu Pharmaceutical Shares and Recording of Extraordinary Income","jir_og_description":"Yomeishu Seizo plans to apply its 101,000 shares of Hisamitsu Pharmaceutical to the tender offer and record an extraordinary income of 413 million yen in the fiscal year ending March 2026.","jir_og_image_url":"\/assets\/og\/company-tender_offer.jpg","jir_chart_data_collection":"[]","ir_related_company":16966,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"tender_offer","footnotes":""},"sector":[],"importance":[],"class_list":["post-27035","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n